The FDA assessed the safety and performance of atidarsagene autotemcel depending on facts from 37 little ones who received atidarsagene autotemcel in two solitary-arm, open-label medical trials and in an expanded accessibility plan.[7] Little ones who been given treatment with atidarsagene autotemcel were when compared to untreated little ones (pur… Read More